Systematically Characterizing Chemical Profile and Potential Mechanisms of Qingre Lidan Decoction Acting on Cholelithiasis by Integrating UHPLC-QTOF-MS and Network Target Analysis - PubMed
- ️Tue Jan 01 2019
Systematically Characterizing Chemical Profile and Potential Mechanisms of Qingre Lidan Decoction Acting on Cholelithiasis by Integrating UHPLC-QTOF-MS and Network Target Analysis
Peng Huang et al. Evid Based Complement Alternat Med. 2019.
Abstract
Qingre Lidan Decoction (QRLDD), a classic precompounded prescription, is widely used as an effective treatment for cholelithiasis clinically. However, its chemical profile and mechanism have not been characterized and elucidated. In the present study, a rapid, sensitive, and reliable ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry method was established for comprehensively identifying the major constituents in QRLDD. Furthermore, a network pharmacology strategy based on the chemical profile was applied to clarify the synergetic mechanism. A total of 72 compounds containing flavonoids, terpenes, phenolic acid, anthraquinones, phenethylalchohol glycosides, and other miscellaneous compounds were identified, respectively. 410 disease genes, 432 compound targets, and 71 related pathways based on cholelithiasis-related and compound-related targets databases as well as related pathways predicted by the Kyoto Encyclopedia of Genes and Genomes database were achieved. Among these pathways and genes, pathway in cancer and MAPK signaling pathway may play an important role in the development of cholelithiasis. EGFR may be a crucial target in the conversion of gallstones to gallbladder carcinoma. Regulation of PRKCB/RAF1/MAP2K1/MAPK1 is associated with cell proliferation and differentiation. Thus, the fingerprint coupled with network pharmacology analysis could contribute to simplifying the complex system and providing directions for further research of QRLDD.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/320e15ee39ba/ECAM2019-2675287.001.gif)
Schematic diagram of present study.
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/037787858e72/ECAM2019-2675287.002.gif)
Representative base peak chromatogram (BPC) of QRLDD in the positive and negative ions mode, respectively. See Table 1 for the peak numbers, and see Section 2.3 Chromatography and MS conditions for UHPLC-QTOF-MS conditions.
![Figure 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/df023a5a6fa6/ECAM2019-2675287.003.gif)
QTOF-ESI-MS/MS spectra and proposed fragmentation pathways of neohesperidin (a), baicalein (b), rutin (c), geniposide (d), jasminoside B (f), chlorogenic acid (g), emodin (h), and acteoside (i) in negative ion mode and dehydrocostuslactone (e) in positive ion mode.
![Figure 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/7bb40df9c971/ECAM2019-2675287.004.gif)
Cholelithiasis-related targets PPI network (confidence score >0.95).
![Figure 5](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/02d03cc0f5da/ECAM2019-2675287.005.gif)
Herb-compound-compound target network of QRLDD (blue circle represents compound targets, cyan diamond represents for compound, and green hexagon represents herb; node size represents the degree).
![Figure 6](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/1bff33247dbd/ECAM2019-2675287.006.gif)
Degree of top 20 compound targets.
![Figure 7](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/78cc8cac7713/ECAM2019-2675287.007.gif)
Illustration of relations among chemical constituent targets and involved pathways of QRLDD (green circle represents compound target, blue triangle represents pathway, green hexagon represents herb, and purple hexagon represents pathway. Node size represents the degree).
![Figure 8](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f6/6335670/2ccfe59cc91c/ECAM2019-2675287.008.gif)
Mechanism of key targets screened by network in the formation of cholelithiasis.
Similar articles
-
Xiao N, Qu J, He S, Huang P, Qiao Y, Li G, Pan T, Sui H, Zhang L. Xiao N, et al. Front Pharmacol. 2020 Jan 31;10:1626. doi: 10.3389/fphar.2019.01626. eCollection 2019. Front Pharmacol. 2020. PMID: 32082152 Free PMC article.
-
Wei TF, Zhao L, Huang P, Hu FL, Jiao JY, Xiang KL, Wang ZZ, Qu JL, Shang D. Wei TF, et al. Front Pharmacol. 2021 Apr 29;12:590994. doi: 10.3389/fphar.2021.590994. eCollection 2021. Front Pharmacol. 2021. PMID: 33995005 Free PMC article.
-
Zhu H, Yin R, Han F, Guan J, Zhang X, Mao X, Zhao L, Li Q, Hou X, Bi K. Zhu H, et al. J Sep Sci. 2014 Dec;37(23):3489-96. doi: 10.1002/jssc.201400728. Epub 2014 Sep 30. J Sep Sci. 2014. PMID: 25195935
-
Li W, Mao X, Wu H, Guo M, Su X, Lu J, Guo Q, Li T, Wang X, Su W, Zhang Y, Lin N. Li W, et al. Phytomedicine. 2020 Feb;67:153156. doi: 10.1016/j.phymed.2019.153156. Epub 2019 Dec 23. Phytomedicine. 2020. PMID: 31901568
Cited by
-
Zhou S, Ai Z, Li W, You P, Wu C, Li L, Hu Y, Ba Y. Zhou S, et al. Front Pharmacol. 2020 Apr 16;11:425. doi: 10.3389/fphar.2020.00425. eCollection 2020. Front Pharmacol. 2020. PMID: 32372953 Free PMC article.
-
Wu Q, Li X, Jiang XW, Yao D, Zhou LJ, Xu ZH, Wang N, Zhao QC, Zhang Z. Wu Q, et al. Front Pharmacol. 2022 Aug 24;13:893244. doi: 10.3389/fphar.2022.893244. eCollection 2022. Front Pharmacol. 2022. PMID: 36091836 Free PMC article.
-
Deng L, Wang S, Leng X, Yao P, Li C, Zheng Y. Deng L, et al. J Radiat Res. 2023 Sep 22;64(5):769-782. doi: 10.1093/jrr/rrad050. J Radiat Res. 2023. PMID: 37429602 Free PMC article.
-
Zhang Y, Zhu M, Zhang F, Zhang S, Du W, Xiao X. Zhang Y, et al. Front Pharmacol. 2019 Sep 18;10:1046. doi: 10.3389/fphar.2019.01046. eCollection 2019. Front Pharmacol. 2019. PMID: 31619994 Free PMC article.
-
Xiao N, Qu J, He S, Huang P, Qiao Y, Li G, Pan T, Sui H, Zhang L. Xiao N, et al. Front Pharmacol. 2020 Jan 31;10:1626. doi: 10.3389/fphar.2019.01626. eCollection 2019. Front Pharmacol. 2020. PMID: 32082152 Free PMC article.
References
-
- Wang C. J., Ma X. M., Wang Z. F., etal. Clinical Observation on Qingre Lidan Decoction in Treatment of Chronic Cholecystitis of Hepatobiliary Damp-Heat Type. Journal of Liaoning University of Traditional Chinese Medicine. 2014;16:183–186.
-
- Zhu X. L. Clinical observation on effect of Corydalis adunca Maxim combined with modified Qingre Lidan Panshi decotion in the treatment of cholelithiasis. Asia-Pacific Traditional Medicine. 2018;14(2):195–196.
-
- Tian J. S., Lin Y. F., Gong Y., etal. Study of the prevention of recurrence of common duct stones after ERCP/EST by Jiajian Huashi Lidan Decoction. Chinese Archives of Traditional Chinese Medicine. 2013;31(1):204–205.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous